Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis

    January 2023 in “ Acta dermato-venereologica ”
    Farnam Barati Sedeh, Thórunn Elísabet Michaelsdóttir, Mattias A S Henning … Kristina Sophie Ibler
    Studysummary In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on medicaljournalssweden.se →
    Discuss this study in the Community →

    Research cited in this study 44

    1. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    2. Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review Dermatologic Therapy · 2022
    3. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    4. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    5. Sublingual Tofacitinib for Alopecia Areata: A Roll-Over Pilot Clinical Trial and Analysis of Pharmacokinetics International Journal of Dermatology · 2021
    6. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    7. Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses Journal of Cosmetic Dermatology · 2021
    8. Treatment of Alopecia Areata in Pre-Adolescent Children with Oral Tofacitinib: A Retrospective Study Pediatric Dermatology · 2020
    9. At The Crossroads Of Two Alopecias: Androgenetic Alopecia Pattern Of Hair Regrowth In Patients With Alopecia Areata Treated With Oral Janus Kinase Inhibitors JAAD case reports · 2020
    10. Emerging Topical and Systemic JAK Inhibitors in Dermatology Frontiers in Immunology · 2019
    11. Low-Dose Tofacitinib for Treating Patients with Severe Alopecia Areata: An Efficient and Cost-Saving Regimen European Journal of Dermatology · 2019
    12. Response of Alopecia Areata of the Beard to Oral Tofacitinib Journal of the American Academy of Dermatology · 2019
    13. Experience with Oral Tofacitinib in Adolescents and Adults with Alopecia Areata Dermatologic Therapy · 2019
    14. Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the European Academy of Dermatology and Venereology · 2019
    15. Combination Tofacitinib and Oral Minoxidil Treatment for Severe Alopecia Areata Journal of The American Academy of Dermatology · 2019
    16. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    17. Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients Dermatologic Therapy · 2019
    18. Tofacitinib Therapy for Children with Severe Alopecia Areata Journal of the American Academy of Dermatology · 2019
    19. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
    20. Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018
    21. Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children Journal of the American Academy of Dermatology · 2018
    22. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
    23. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    24. Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Journal of the American Academy of Dermatology · 2018
    25. Nail Involvement in Patients with Moderate-to-Severe Alopecia Areata Treated with Oral Tofacitinib Journal of Dermatological Treatment · 2018
    26. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    27. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients International Journal of Trichology · 2018
    28. Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study Acta dermato-venereologica · 2018
    29. Alopecia Areata: Treatment Options and Efficacy Journal of the American Academy of Dermatology · 2017
    30. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
    31. Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series Journal of the American Academy of Dermatology · 2017
    32. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata Journal of cutaneous medicine and surgery · 2017
    33. Treatment of Alopecia Areata With Tofacitinib JAMA Dermatology · 2017
    34. Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis Journal of the American Academy of Dermatology · 2017
    35. Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
    36. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    37. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    38. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    39. Familial Aggregation of Alopecia Areata Journal of the American Academy of Dermatology · 2016
    40. Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth Science Advances · 2015
    41. Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015
    42. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    43. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012
    44. Alopecia Areata Update Journal of the American Academy of Dermatology · 2010

    Related research 3

    1. Serum Zinc Concentration in Patients With Alopecia Areata Acta dermato-venereologica (Print) · 2023
    2. Treatment With Oral Janus Kinase Inhibitors in Adult Patients With Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the American Academy of Dermatology · 2023
    3. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014